Anti-CD7 antibody [SP94],Abcam,AB183325

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Human

Application

IHC-P

Platform ID

BAB004796990

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Abcam

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Email:

[email protected]

Product Specifications
Scientific Background

Specifications

NameAnti-CD7 antibody [SP94]
Cat. No.AB183325
HostRabbit
IsotypeIgG
ReactivityHuman
ApplicationIHC-P
ClonalityMonoclonal
Clone NumberSP94
Concentration0.056 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 - 7.4 Preservative: 0.1% Sodium azide Constituents: PBS, 1% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Transmembrane glycoprotein expressed by T-cells and natural killer (NK) cells and their precursors (PubMed : 7506726). Plays a costimulatory role in T-cell activation upon binding to its ligand K12/SECTM1 (PubMed : 10652336). In turn, mediates the production of cytokines such as IL-2 (PubMed : 1709867). On resting NK-cells, CD7 activation results in a significant induction of interferon-gamma levels (PubMed : 7506726). See full target information CD7

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.